PET Imaging of CD38 and IND enabling studies of [89Zr]Zr-DFO-Isatuximab
[<sup>89</sup>Zr]Zr-DFO-Isatuximab showed high specificity to CD38 positive cells, had estimated effective doses comparable to other clinically relevant <sup>89</sup>Zr-labeled antibodies, and can be prepared using GMP practices for clinical use.
Authors
- Solana Fernandez
- Smith Giri (ORCID: https://orcid.org/0000-0002-1827-5032)
- Jonathan McConathy (ORCID: https://orcid.org/0000-0003-4681-2322)
- Hailey A. Houson (ORCID: https://orcid.org/0000-0001-8566-2369)
- Suzanne E. Lapi (ORCID: https://orcid.org/0000-0003-0090-0191)
- Brian D. Wright
- Kadir Gultekin (ORCID: https://orcid.org/0000-0002-9736-6302)
Institutions
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Molecular Imaging and Biology
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1007/s11307-025-02062-9
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00